Median Technologies has secured up to €47.5m ($49.9m) to support the regulatory filing and commercialisation efforts for its suite of artificial intelligence (AI)-powered early lung cancer ...

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Median Technologies eyonis lung cancer screening (LCS) diagnostic has met the primary endpoint in a second pivotal study ...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) are invited to ...

Last month, Median said that it was preparing to file for FDA approval of iBiopsy for lung cancer screening, aiming at a green light for the SaMD before the end of 2023, based on study data ...

SOPHIA ANTIPOLIS, France, March 03, 2025--Median Technologies announces the availability of the preparatory documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025 SOPHIA ...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of ...